EP0031

PreclinicalSmall molecule

EEllipses Pharma

EP0031 is one of 9 small molecule programs targeting NSCLC. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLCRecruiting

NSCLCPreclinical

Recruiting

Competition

Competitive Landscape

14 competitors in NSCLC

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

5 2

Alunbrig

Takeda

Phase 2

2 3

Poziotinib

Spectrum Pharmaceuticals, Inc

Phase 3

1 4

Tyrosine Kinase Inhibitor

Pfizer

Phase 2

1 5

SKB264

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2

2 6

SYS6010

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 1

2 7

Alimta

GGynecologic Oncology Group

Preclinical

1 8

Platinum Chemotherapy

Roche

Preclinical

1 9

EP0031

EEllipses Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

NSCLC

NCT05443126

Clinical

Trials by Indication[1]

NSCLC1 trial

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting·EEllipses Pharma·Preclinical·NCT05443126·265 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EP0031. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EP0031 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EP0031. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ellipses Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEllipses Pharma

EP0031

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

NSCLC1 trial

References

Drug Info

Quick Facts

Related News